PROGNOSTIC VALUE OF MAGE-A AND NY-ESO-1 EXPRESSION IN PHARYNGEAL CANCER
PROGNOSTIC VALUE OF MAGE-A AND NY-ESO-1 EXPRESSION IN PHARYNGEAL CANCER
复制标题
DOI：
10.1002/hed.21314
复制
发表时间：
2010-09-01
影响因子：
2.9
通讯作者：
Grgic, Marko
中科院分区：
文献类型：
--
作者：
Pastorcic-Grgic, Marija;Sarcevic, Bozena;Grgic, Marko
Background. The prognostic value of cancer testis antigens in pharyngeal cancer is understudied.Methods. We recruited 90 patients who were treated for pharyngeal cancer. Monoclonal antibodies 57B and B9.8.1.1 were used for detection of MAGE-A and NY-ESO-1 genes.Results. MAGE-A and NY-ESO-1 gene products were detectable in 70.0% and 33.3% of pharyngeal tumors, respectively. No correlation was established between MACE-A and NY-ESO-1 expression and TNM staging at presentation. Survival analysis showed a trend toward a shorter 5-year disease-free survival in the group of patients with MACE-A-positive tumors (log-rank test, p = .122). In contrast, a trend toward a prolonged 5-year disease-free survival was observed in the group of patients with NY-ESO-1-positive tumors (log-rank test, p = .219).Conclusion. In a large population of patients with pharyngeal cancer and available 5-year survival data, prognosis tended to be poorer with MAGE-A expression and better with NY-ESO-1 expression, but the correlations did not reach statistical significance. (c) 2009 Wiley Periodicals, Inc. Head Neck 32: 1178-1184, 2010
